Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
RHPN1-AS1
Specific or universal ncRNAs
Specific ncRNAs
Class
Long noncoding RNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
miR-299-3p/TNFSF12
Cancer name
Non-Small Cell Lung Cancer
Cancer site
Lung
Treatment type
Chemotherapy
Drug
Gefitinib
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Up
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
RHPN1-AS1 modulates gefitinib resistance through miR-299-3p/TNFSF12 pathway in NSCLC. Our findings indicate that RHPN1-AS1 may serve as not only a prognostic biomarker for gefitinib resistance but also as a promising therapeutic biomarker and target for the treatment of NSCLC patients.
Tissue resource
non-small cell lung cancer samples and adjacent non-tumor tissues
non-small cell lung cancer cell lines A549
non-small cell lung cancer cell lines H1975
non-small cell lung cancer cell lines H1299
non-small cell lung cancer cell lines HCC827
non-small cell lung cancer cell lines PC9
human bronchial epithelial cell lines 16HBE
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
the First Hospital of China Medical University
the Cell Culture Center, Chinese Academy of Medical Sciences
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.